Life sciences company Neogen (NASDAQ:NEOG) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.4% year on year to $221 million. The company’s full-year revenue guidance of $895 million at the midpoint came in 1.7% below analysts’ estimates. Its non-GAAP profit of $0.10 per share was 13% below analysts’ consensus estimates.
Neogen (NEOG) Q1 CY2025 Highlights:
Revenue: $221 million vs analyst estimates of $224.2 million (3.4% year-on-year decline, 1.5% miss)
Adjusted EPS: $0.10 vs analyst expectations of $0.12 (13% miss)
Adjusted EBITDA: $48.51 million vs analyst estimates of $52.73 million (22% margin, 8% miss)
EBITDA guidance for the full year is $195 million at the midpoint, below analyst estimates of $207.8 million
Operating Margin: 2.5%, down from 5.3% in the same quarter last year
Market Capitalization: $1.53 billion
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.